Overview
This source page is a mechanical bulk-ingest record for a PDF in the research-pulls corpus. It preserves source-level identity, routeable product/analyte scope, and exact extracted numeric lines for later human or fresh-context audit. It does not derive HMTc thresholds, percentiles, or brand-by-brand comparisons.
Key numbers
The worker extracted the full PDF text with layout preservation twice and compared extraction hashes before commit. The following lines are copied from numeric/table-bearing regions of the PDF and retain the source units and wording where legible:
- © 2026 Asiri. This is an open-access menib). Meanwhile, epigenetic modulators like azacitidine emphasize the wider
- 20% (3). Our knowledge of AML can be enhanced by understanding Conversely, targeted medicines suppress oncogenic drivers to affect
- Additional fusion genes, such as RUNX1-RUNX1T1 in AML-M2 removing the maturation barrier. Notable instances include arsenic
- serves as the foundation of treatment (11–13, 16, 18, 19). The limit of myelodysplastic syndromes (MDS) often presenting with chronic
- oped drugs such FLT3, BCL-2, and HDAC inhibitors in conjunction ous monitoring and proactive intervention due to their unstable
- tation heals about 60% of younger patients (20). Poor results are still hallmark of Acute Myeloid Leukemia (AML). These malignant cells
- RUNX1, CEBPA, and KAT6A are frequently altered or expressed immunophenotyping are usually used to demonstrate that 20% or
- istic of both AML and Myelodysplastic Syndromes (MDS) (41–45). There are notable differences in the prevalence of AML among vari-
- bolic changes also affect the bone marrow niche, which promotes LSC tions and a lack of suitable healthcare infrastructure (52, 53).
- AML tality rates for those diagnosed after age 65 surpass 90% (52).
- ciated with DNA damage and clonal haematopoiesis. Workers in sectors challenges. According to clinical data, up to 30–40% of patients’ relapse
- Additionally, a large number of biomarkers function as indica- during and after treatment (70, 71). Additionally, about 20–25% of
- potential role in directing differentiation therapy. AML. Research indicates that 66.7% of AML patients exhibit CD34
- cytometry, with positivity defined as ≥10% of blast cells showing
- PML-RARA fusion gene is found in approximately 98% of patients due all and disease-free survival and lower rates of full remission.
- 97% event-free survival rates at 2 years (65–67). Diagnostic tools such 3.3.1 NPM1 mutation
- responsiveness to ATRA and ATO, marking them as key indicators of About 30% of AML cases had these mutations, which are associated
- treatment resistance. Identifying these variants is essential for accurate with higher WBC counts, decreased CD34 expression, and 58–60%
- The chromosomal rearrangement t(8;21) (q22;q22) results in the According to guidelines from the National Comprehensive
- is present in around 5–10% of all AML cases and 7–12% of adult cases validate this strategy. Elevated NPM1 levels in peripheral blood may
- in around 30% of patients. Tyrosine kinase domain (FLT3-TKD) methylation of DNA and histones, which hinders hematopoietic cell
- mutations account for about 7%, while internal tandem duplica- differentiation and drives leukemogenesis (79).
- tions (FLT3-ITD) account for about 25%. FLT3-ITD mutations are These mutations are constant across age groups, occurring in
- frequently connected to poor prognosis and normal karyotype 15–20% of AML patients and 25–30% of AML cases with normal
- appear alongside PML-RARA rearrangements (74). Therapeutically, promotes cell differentiation, receiving FDA approval in 2018 for
- pressive function, leading to uncontrolled cell proliferation. Although about 20–30%, resulting in unique molecular subtypes that influence
- 10% of newly diagnosed AML cases, 20–37% of therapy-related AML (84, 85). NPM1c (mutant NPM1) mislocalizes to the cytoplasm,
- cases, and up to 70% of AML cases with complicated karyotypes— impairing nucleolar function and ARF suppression, whereas FLT3-
- sion (CR) rate of only 28.6%, even following hematopoietic stem cell augments clonal dominance by allele amplification, and elucidates
- median overall survival of 6–8 months. prognosis (86, 87). On the other hand, the interplay between
- 82%, highlighting its potential as a targeted treatment for TP53- IDH2R140 enrichment, and superior outcomes compared to NPM1/
- mutated AML and myelodysplastic syndromes (MDS). European FLT3-ITD, with IDH co-mutation mitigating the detrimental effects
- adverse genetics achieve cure rates of merely 10–15%, hence requiring traditional chemotherapeutics that focus on eliminating proliferating
- malignancies. However, its clinical adoption did not occur until the toxicity (Figure 3; Table 1).
- TABLE 1 Key differentiation -inducing agents used in the treatment of acute myeloid leukaemia (AML) and acute promyelocytic leukaemia (APL) highlighting their molecular targets, relevant
- venetoclax and bleximenib diagnosed, intensive chemotherapy- rearrangements (KMT2Ar),
- TABLE 2 Key biomarkers in acute myeloid leukemia (AML) with their types, clinical significance, and associated subtypes or features.
- FLT3-ITD/TKD Tyrosine kinase mutations Poor prognosis with FLT3-ITD; targetable with TKIs Normal karyotype AML; co-mutates with NPM1
- (NBs) are reassembled, and tumor suppressor pathways involving p53 median maximum 2-HG reduction of 97%, compared to only 12%
- kemic blasts to differentiate into granulocytes, whereas at higher con- with a median reduction of 74%, while those with partial or no
- mature myeloid cells. No such effect was observed in cells with wild- approximately 23%, with responses being more enriched in patients
- 4.2.5 Azacitidine: epigenetic modulator with cell transplantation with CR/CRh of 23.4% and ORR of 46.9% in a
Methods (brief)
- C/EBPα) are present in myelodysplastic syndromes (MDS), some of targeted inhibitors, such as IDH and Menin inhibitors, their treatment
- serves as the foundation of treatment (11–13, 16, 18, 19). The limit of myelodysplastic syndromes (MDS) often presenting with chronic
- ture precursor cells (blasts) in the bone marrow and peripheral circu- AML patient samples (32). Recent investigations indicate that these
- istic of both AML and Myelodysplastic Syndromes (MDS) (41–45). There are notable differences in the prevalence of AML among vari-
- mutated AML and myelodysplastic syndromes (MDS). European FLT3-ITD, with IDH co-mutation mitigating the detrimental effects
- et al. Eprenetapopt (APR-246) and Azacitidine in TP53-mutant Myelodysplastic syn- 102. Germain P, Iyer J, Zechel C, Gronemeyer H. Co-regulator recruitment and the
-
- Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, et al. 105. Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, et al.
Implications
This page makes the source discoverable for category-level evidence routing. Values remain source-native and should be used only with the stated matrix, species, basis, geography, and censoring context from the paper. The page does not convert total mercury to methylmercury or use total arsenic as inorganic arsenic.
Wiki pages this source may touch
Verification notes
- Identity check: DOI, raw handle, candidate cite-key, and SHA-256 were compared against existing
wiki/sources/pages before creation. - Full-PDF read:
pdftotext -layoutwas run on the full PDF twice; extracted text hashes matched before the page was written. - Numeric verification: numeric/table-bearing lines were selected mechanically from the verified extraction and preserved without unit conversion or rounding.
- Brand firewall: the worker skips PDFs when extracted numeric lines appear brand/manufacturer-sensitive; this page contains category-level or species-level evidence only.
- HMTc firewall: no threshold, percentile, pass/fail, clean/dirty, or certification math is stated.
Update history
The five most recent substantive edits to this page, classified major (evidence or structure moved), correction (a published value or statement was wrong and has been fixed), or minor (narrative rewritten without changing the underlying evidence). Each description is derived from what the edit did to this page; the linked commit is the authoritative record, routine regeneration passes are excluded, and the full version history lives in git. When DOI minting comes online (see schema docs), each entry below will also link to a version-pinned DataCite DOI.